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TO THE EDITOR
Recently, a pathological role for IFN-a
in the development of psoriasis has
been suggested. Clinically, exacer-
bation of psoriasis has often been
observed after starting IFN-a therapy
for other diseases. IFN-a induced by
topical application of a Toll-like recep-
tor-7 agonist can also trigger the devel-
opment of psoriasis (Gilliet et al.,
2004). Histopathologically, plasmacy-
toid dendritic cells (pDCs), the princi-
pal IFN-a–producing cells, infiltrate into
the psoriatic lesions in the early phase
(Wollenberg et al., 2002; Gilliet et al.,
2004). In a xenograft model, in which
human psoriatic skin was transplanted
onto immunodeficient mice, Nestle
et al. (2005) clearly demonstrated that
blocking IFN-a signaling prevents the
T cell–dependent development of psori-
asis and that inhibiting the production
of IFN-a by pDCs completely sup-
presses the development of a psoriatic
phenotype. IFN-a may mediate the
activation of T cells directly or through
the induction of myeloid dendritic
cell activation and/or maturation. The
involvement of keratinocytes, however,
remains unclear.
We recently reported that IL-22 rece-
ptor (IL-22R) expression is enhanced
in the epidermis of psoriasis compared
with normal skin (Tohyama et al.,
2009). IL-22, a member of the IL-10
family, is one of the most impor-
tant cytokines in the pathogenesis of
psoriasis, contributing to proliferation/
differentiation of keratinocytes and to
the production of antimicrobial pep-
tides, cytokines, and chemokines (Wolk
et al., 2006; Sa et al., 2007). Receptors
for IL-22 include IL-22R and IL-10
receptor 2 (IL-10R2). IL-10R2 is widely
expressed on various cells and tissues.
On the other hand, IL-22R expression is
limited mainly to epithelial cells, includ-
ing epidermal keratinocytes, where
IL-22R expression levels are altered by
cytokine stimulation. Increased IL-22R
expression strengthens the responsive-
ness of keratinocytes to IL-22 stimulation
(Tohyama et al., 2009). These findings
suggest that an increase in IL-22R
expression on epidermal keratinocytes
is an important feature in psoriasis.
We hypothesized that IFN-a en-
hances IL-22R expression on epidermal
keratinocytes. To examine this, we used
a living skin equivalent (LSE) model
(Yang et al., 2005), as IL-22R expres-
sion of cultured keratinocyte mono-
layers is suppressed relative to that
of stratified epidermal keratinocytes,
including those in the LSE (Sa et al.,
2007). To prepare the LSE, normal
human epidermal keratinocytes and
fibroblasts were isolated from nonle-
sional human skin obtained from plastic
surgery and then cultured. A collagen
gel containing the fibroblasts was
prepared, and the keratinocytes were
seeded onto the concave surface of the
contracted gel. When the keratinocytes
reached confluence, the LSE was raised
to the air–liquid interface, and cornifi-
cation medium was added. Experiments
were conducted from 8 to 12 days
after air-lifting. Total RNA or protein
was extracted from the LSE epidermis
for real-time reverse transcription-PCR
analysis or western blotting, respec-
tively. For immunofluorescence stain-
ing, frozen LSE sections (5mm) were
fixed in cold acetone or methanol
and reacted with primary antibodies.
Sections were then incubated with
donkey anti-rabbit or anti-goat anti-
bodies labeled with Alexa Fluor 488
(Molecular Probes, Eugene, OR). Alter-
natively, LSE epidermis was treated
with trypsin, and flow cytometry ana-
lysis (FCM) was performed as described
previously (Tohyama et al., 2009). For
each examination, results were confirmed
in three independent experiments.
LSE was treated with IFN-a for 4, 8,
or 24 hours. IFN-a markedly enhanced
IL-22R mRNA expression in the epi-
dermis after 4 hours of stimulation
(Figure 1a), and this increase was
dose dependent (Figure 1b). In contrast,
IL-10R2 mRNA expression level was
not changed (Figure 1c). The expression
of IL-20R1 and IL-20R2, receptors for
IL-10 family cytokines other than IL-22,
was also unaffected by IFN-a.
LSE treated with or without IFN-a for
24 hours was snap-frozen, and immuno-
fluorescence staining was performed
using anti-IL-22R antibody (R&D sys-
tems, Minneapolis, MN). IL-22R expres-
sion was increased relative to controls in
the LSE epidermis treated with IFN-a
(Figure 1d). Increased IL-22R expression
on keratinocyte cell surfaces was also
observed by FCM analysis (Figure 1e).
To examine whether the response to
IL-22 is increased by IFN-a treat-
ment, phosphorylation of signal trans-
ducer and activator of transcription 3
(STAT3) was examined by western
blotting. Anti-phospho-STAT3 antibody
was purchased from Cell Signaling
Technology (Danvers, MA). As shown
in Figure 2a, STAT3 was phosphory-
lated at 30 and 60 minutes after IL-22
stimulation in the epidermis of LSE.
When LSE was pretreated with
IFN-a for 24 hours, phosphorylation
of STAT3 was markedly augmented.
See related commentary on pg 1759
Abbreviations: FCM, flow cytometry; IL-10R, IL-10 receptor; IL-22R, IL-22 receptor; LSE, living skin
equivalent; pDC, plasmacytoid dendritic cell; STAT3, signal transducer and activator of transcription 3
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Immunostaining revealed that phospho-
STAT3 appeared in the nuclei of IFN-a-
pretreated keratinocytes after IL-22 sti-
mulation, whereas staining was weak
and the percentage of phospho-STAT3-
positive cells was low in untreated
keratinocytes, even after IL-22 addition
(Figure 2b and c).
We clearly demonstrated here that
IFN-a strengthens the responsiveness of
epidermal keratinocytes to IL-22 via
increased IL-22R expression. These
findings explain the exacerbation of
psoriasis due to IFN-a therapy and
support the theory that IFN-a triggers
the development of psoriatic lesions.
However, this mechanism is not spe-
cific to psoriasis. IL-22 is required for
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Figure 1. Enhancement of IL-22 receptor (IL-22R) expression in keratinocytes by IFN-a. Living skin equivalent was treated with IFN-a for the indicated
time and at the indicated concentrations (a–e). mRNA expression of IL-22R (a, b) or other receptors (c) was analyzed and normalized to glyceraldehyde-
3-phosphate dehydrogenase control. The results are expressed as the mean±standard deviation. IL-22R protein expression in keratinocytes was
analyzed by immunofluorescence staining (d) or by flow cytometry analysis (e). Bar¼ 100mm.
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Figure 2. Enhancement of IL-22 receptor (IL-22R)-induced signal transducer and activator of transcription 3 (STAT3) phosphorylation by IFN-a. Living skin
equivalent (LSE) was pretreated with IFN-a for 24 hours and then stimulated with IL-22 for 30 and 60 minutes (a) or for 60 minutes (b). pSTAT3 was analyzed
by western blotting (a) or immunofluorescence staining (b). Nuclear staining of pSTAT3 was apparent in the keratinocytes of LSE pretreated with IFN-a (b).
Bar¼100 mm. Percentage of nuclear pSTAT3-positive cells was measured, and the results are expressed as the mean±standard deviation (c). Statistical
analysis of the data was evaluated using Student’s t-test.
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host defenses against microbial infec-
tion, inflammation, and injury (Ouyang,
2010). Increasing IL-22R expression in
keratinocytes by IFN-a may be one of
the defense systems of injured skin.
Damage causes infiltration of pDCs,
which are activated by self-nucleic acid
derived from damaged keratinocytes or
other cells via Toll-like receptors 7 and
9, producing IFN-a/b (Gregorio et al.,
2010). Although the detailed mechan-
isms remain unclear, IFN-a/b produced
by pDCs influences IL-17- and IL-22-
producing T cells by activation of
myeloid dendritic cells (Gregorio
et al., 2010). IL-22 signals via IL-22R
inhibit keratinocyte terminal differen-
tiation, causing thickening of the
epidermis (Sa et al., 2007). IL-22 also
induces production of heparin-binding
epidermal growth factor-like growth
factor from keratinocytes and may
mediate the proliferation of the epider-
mis (Sa et al., 2007; Tohyama et al.,
2009). Moreover, IL-22 induces expres-
sion of several genes in keratinocytes,
such as human b-defensin 2 and S100
family genes, that are antimicrobial
proteins (Wolk et al., 2006; Ouyang,
2010). Although these cellular responses
will usually become downregulated after
the repair of injury, the responses may
trigger the development of lesions in
psoriasis. Further studies will be neces-
sary to clarify this mechanism.
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TO THE EDITOR
Significant advances in the understand-
ing of the biology and molecular
mechanisms of cancer have allowed
the development of new targeted agents
for the treatment of melanoma. Pre-
vious studies showed that BRAF and
NRAS mutations were observed in
approximately 40–60% and 15–20% of
cutaneous melanomas (Chapman et al.,
2011; Lee et al., 2011), respectively.
Most of the data regarding genetic
mutations associated with melanomas
have been obtained from Caucasian
cohorts, and comprehensive screenings
of the Chinese population are limited.
In this study, we examined the mutation
profiles using the MassARRAY System
(Sequenom, San Diego, CA) to deter-
mine the prevalence of oncogene
mutations in melanoma patients from
southern China.
The MassARRAY platform provides
a superior technology for the screening
of 238 hot-spot cancer mutations in
19 common oncogenes: ABL1, AKT1,
AKT2, BRAF, CDK4, EGFR, ERBB2,
FGFR1, FGFR3, FLT3, JAK2, KIT, MET,
HRAS, KRAS, NRAS, PDGFRA, PIK3CA,
and RET (Supplementary Table S1 on-
line). A total of 114 formalin-fixed and
paraffin-embedded melanoma lesions
were examined: 28 paired primary acral
melanomas with corresponding lymph
node metastasis; 28 mucosal melano-
mas; and 30 non-chronic sun-induced
damage melanomas (Supplementary
Table S2–4 online). The study protocol
was approved by the research ethics
committee of Sun Yat-Sen University
Cancer Center, China.
At least one mutation was detected in
33 of the 86 (38.4%) melanomas, with
mutations observed in BRAF (16.3%),
NRAS (10.5%), KIT (5.8%), EGFR
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